Moderna shares surge as melanoma vaccine with Merck succeeds in large trial
Moderna and Merck announced positive interim results from a late-stage trial of their melanoma vaccine, Intismeran, combined with Keytruda. The treatment met primary and secondary goals, reducing cancer recurrence and spread. Moderna's shares surged 60% premarket, while Merck rose 7.5%. Analysts expect the therapy could generate $3 billion by 2035. The trial involved 1,137 high-risk melanoma patients.
How this was made
The 30-second read
Why it matters
The trial met primary and secondary endpoints, prompting a sharp stock rally for both companies.
Market read
First‑time disclosure of pivotal trial data for a large‑cap biotech partnership, driving significant price moves.
What to watch
Regulatory timeline and potential competition from other mRNA cancer candidates could temper upside.
Background
Moderna and Merck disclosed interim results of a late‑stage melanoma vaccine trial, the first public release of this data.
Ticker impact
Moderna announced positive interim results for its melanoma vaccine trial, sending the stock up 60% pre‑market.
Further upside if full data confirm efficacy; near‑term volatility expected.
First disclosure of pivotal trial data for a large‑cap biotech; market reacted strongly.
Merck's Keytruda combined with Moderna's vaccine showed efficacy, lifting Merck shares 7.5% pre‑market.
Potential incremental upside as partnership gains traction.
First report of trial success involving Merck; market response confirms material impact.
Market effects
Strengthens biotech and oncology sectors, may lift peers developing mRNA cancer vaccines.
Positive for US biotech market; limited immediate effect elsewhere.
Highlights mRNA platform versatility, could influence global pharma collaborations.
Counterpoint
Skeptics may question durability of interim data and long‑term safety, suggesting caution.
Key entities
- CompanyModerna
mRNA vaccine developer
- CompanyMerck
Immunotherapy leader, maker of Keytruda
